Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 4Phase NA 2Phase 4 2Phase 1 2

Status

Recruiting 3Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Neoplasms 1Multiple Myeloma 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Cisplatin 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × apixaban × Clear all
NCT02958969 2019-12-17

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Dana-Farber Cancer Institute

Phase 4 Completed
50 enrolled 5 charts
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

NCT02581176 2018-06-26

CAP

University Hospital, Akershus

Phase 4 Completed
300 enrolled

Neoplasms, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡